European Commission Authorizes Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in 1L CLL June 2, 2026
DARZALEX® (daratumumab) injectable approved for administration by patients or caregivers for treatment of multiple myeloma June 2, 2026
Opdivo in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma June 2, 2026
Datroway approved in the US in 1L metastatic TNBC patients not PD-1/PD-L1 inhibitor candidates May 26, 2026
US FDA Approves INQOVI® in Combination with Venetoclax in AML Patients Ineligible for Intensive Induction Chemo May 21, 2026
Enhertu approved for use before surgery based on DESTINY-Breast11 Ph 3 trial and following surgery based on DESTINY-Breast05 Ph 3 trial in HER2-positive early breast cancer May 21, 2026
FDA Approves BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner’s National Priority Voucher May 12, 2026
FDA Approves VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer May 6, 2026
FDA Approves Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis May 6, 2026
Ojemda® approved in the EU in R/R pediatric low-grade glioma regardless of BRAF alteration April 28, 2026
ZEPZELCA + Tecentriq approved for use in Australia and Singapore as 1L maintenance treatment for adult patients with ES-SCLC April 21, 2026
Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma April 21, 2026
European Commission Approves KEYTRUDA + Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens April 7, 2026
Japan’s MHLW approves risovalisib (Risovalisib Mesilate Hydrate or Heitzexin) after chemo for ovarian clear cell carcinoma with advanced PIK3CA gene mutations March 31, 2026
FDA Approves Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer March 31, 2026
ENHERTU Followed by THP Approved in China for the Neoadjuvant Treatment of HER2+ve Breast Cancer March 31, 2026
Opdivo combination regimens received FDA approval for previously untreated, Stage III or IV cHL and EC approval in R/R cHL after one prior line of therapy March 24, 2026
Imfinzi approved in the EU in patients with early gastric and gastroesophageal cancers March 17, 2026
European Commission approves AKEEGA (niraparib & abiraterone dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic HSPC patients March 10, 2026
SC RYBREVANT approved by European Commission for Q3W and Q4W dosing for patients with advanced EGFR-mutated NSCLC March 3, 2026
